Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for NUT carcinoma (midline carcinoma with NUTM1 rearrangement), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Misdiagnosis and delay: NUT immunohistochemistry should be routine in poorly differentiated midline tumours.
BET inhibitor responses are short: degraders, CDK9 and HDAC combinations, and chemotherapy combinations are in trials.
Thrombocytopenia limits BET inhibitor dosing.
No randomised trials exist; the registry is the evidence base.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Chau and colleagues, JCO: fusion partner and initial treatment predict survival.
Birabresib (OTX015) and molibresib phase 1 cohorts.
Filippakopoulos and colleagues, Nature: proof of concept for BET inhibition.
Haack and colleagues: highly specific antibody enables diagnosis.
French and colleagues identify the fusion gene.